Skip to main content
Erschienen in: Supportive Care in Cancer 2/2006

01.02.2006 | Original Article

Prospective, double-blind, randomized trial of equimolar mixture of nitrous oxide/oxygen to prevent pain induced by insertion of venous access ports in cancer patients

verfasst von: Marie Cécile Douard, Mario di Palma, Patricia d’Agostino, Sylvie Chevret, Irène Kriegel, Bruno Falissard, Patrick Thierry, Brigitte George, Laurence Bussières, Jean-Louis Misset

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

Background

To assess the efficacy of equimolar mixture of nitrous oxide/oxygen (EMNO) to prevent pain induced by venous access ports (VAPs) implantation in cancer patients.

Patients and methods

In a randomized, double-blind study on an adult population not knowing the effects of EMNO, cancer patients were randomly assigned to breath via a facial mask, EMNO or a placebo mixture comprising 50% oxygen and 50% nitrogen. The primary end-point was the patients’ assessment of the severity of pain evaluated using a visual analog scale (VAS, 0 to 100) and the proportion of patients suffering pain in each group. The secondary criteria were side effects, tolerability of EMNO, and the level of satisfaction of both the patients and the medical team.

Results

Eighty-three adults (42 in the EMNO group and 41 in the placebo group) were included. VAPs were implanted in the jugular vein in 95% of patients. In the placebo group, 78% of the patients declared that they found VAP implantation painful vs. 34% in the EMNO group (p=0.001). The severity of the pain was reduced by 50% in the EMNO group in comparison with placebo (p=0.0125). Although the median time to perform implantation was strictly identical in both groups (20 min), the estimated duration of surgery seemed longer to patients in the control group. Patient and investigator satisfaction indexes were >90% in both groups.

Conclusion

EMNO provides an effective solution for the prevention of pain during placement of VAPs.
Fußnoten
1
In the EMNO group, one patient was unable to evaluate his pain with the VAS.
 
Literatur
1.
Zurück zum Zitat Annequin D, Carbajal R, Chauvin P, Gall O, Tourniaire B, Murat I (2000) Fixed 50% nitrous oxygen mixture for painful procedures: a French survey. Pediatrics 105:1–6CrossRefPubMed Annequin D, Carbajal R, Chauvin P, Gall O, Tourniaire B, Murat I (2000) Fixed 50% nitrous oxygen mixture for painful procedures: a French survey. Pediatrics 105:1–6CrossRefPubMed
2.
Zurück zum Zitat Berkowitz B, Finck A, Ngai S (1976) Nitrous oxide “analgesia”:resemblance to opioid action. Science 194:967–968PubMed Berkowitz B, Finck A, Ngai S (1976) Nitrous oxide “analgesia”:resemblance to opioid action. Science 194:967–968PubMed
3.
Zurück zum Zitat Berkowitz B, Finck A, Ngai S (1977) Nitrous oxide “analgesia”:reversal by naloxone and development of tolerance. J Pharmacol Exp Ther 203:539–547PubMed Berkowitz B, Finck A, Ngai S (1977) Nitrous oxide “analgesia”:reversal by naloxone and development of tolerance. J Pharmacol Exp Ther 203:539–547PubMed
4.
Zurück zum Zitat Evans J, Buckley S, Alexander H, Gilpin A (1995) Analgesia for reduction of fractures in children: a comparison of nitrous oxide with intramuscular sedation. J Pediatr Orthop 15:73–77PubMed Evans J, Buckley S, Alexander H, Gilpin A (1995) Analgesia for reduction of fractures in children: a comparison of nitrous oxide with intramuscular sedation. J Pediatr Orthop 15:73–77PubMed
5.
Zurück zum Zitat Fauroux B, Onody P, Tourniaire B, Gall O, Clément A (2001) Nitrous oxide improves the comfort and the tolerance of fiberoptic bronchoscopy in children. Eur Respir J 18:190S Fauroux B, Onody P, Tourniaire B, Gall O, Clément A (2001) Nitrous oxide improves the comfort and the tolerance of fiberoptic bronchoscopy in children. Eur Respir J 18:190S
6.
Zurück zum Zitat Flomenbaum N, Gallagher E, Eagen K, Jacobson S (1979) Self-administered nitrous oxide:an adjunct analgesic. JACEP 8:95–97PubMed Flomenbaum N, Gallagher E, Eagen K, Jacobson S (1979) Self-administered nitrous oxide:an adjunct analgesic. JACEP 8:95–97PubMed
7.
Zurück zum Zitat Gall O, Annequin D, Benoit G, Glabeke E, Vrancea F, Murat I (2001) Adverse events of premixed nitrous oxide and oxygen for procedural sedation in children. Lancet 358:1514–1515CrossRefPubMed Gall O, Annequin D, Benoit G, Glabeke E, Vrancea F, Murat I (2001) Adverse events of premixed nitrous oxide and oxygen for procedural sedation in children. Lancet 358:1514–1515CrossRefPubMed
8.
Zurück zum Zitat Gillman M, Lichtigfeld F (1994) Opioid properties of psychotropic analgesic nitrous oxide (laughing gas). Perspect Biol Med 38:125–138PubMed Gillman M, Lichtigfeld F (1994) Opioid properties of psychotropic analgesic nitrous oxide (laughing gas). Perspect Biol Med 38:125–138PubMed
9.
Zurück zum Zitat Gillman M, Lichtigfeld F (1980) Paradoxical effect of naloxone on nitrous oxide analgesia in man. Eur J Pharmacol 61:175–177CrossRefPubMed Gillman M, Lichtigfeld F (1980) Paradoxical effect of naloxone on nitrous oxide analgesia in man. Eur J Pharmacol 61:175–177CrossRefPubMed
10.
Zurück zum Zitat Hennequin M, Faulks D (2001) Indications de sédation par inhalation d’un mélange équimolaire d’oxygène et de protoxyde d’azote en odontologie. Entretiens de Bichat, E. S. F. 2001. Paris Hennequin M, Faulks D (2001) Indications de sédation par inhalation d’un mélange équimolaire d’oxygène et de protoxyde d’azote en odontologie. Entretiens de Bichat, E. S. F. 2001. Paris
11.
Zurück zum Zitat Jevtovic-Todorovic V, Todorovic S, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski C, Olney J (1998) Nitrous oxide (laughing gas) is an NMDA antagonists, neuroprotectant and neurotoxin. Nat Med 4:460–463CrossRefPubMed Jevtovic-Todorovic V, Todorovic S, Mennerick S, Powell S, Dikranian K, Benshoff N, Zorumski C, Olney J (1998) Nitrous oxide (laughing gas) is an NMDA antagonists, neuroprotectant and neurotoxin. Nat Med 4:460–463CrossRefPubMed
12.
Zurück zum Zitat Kaufman E, Chastain D, Gaughan A, Gracely R (1992) Staircase assessment of the magnitude and time course of 50% nitrous-oxide analgesia. J Dent Res 71:1598–1603PubMed Kaufman E, Chastain D, Gaughan A, Gracely R (1992) Staircase assessment of the magnitude and time course of 50% nitrous-oxide analgesia. J Dent Res 71:1598–1603PubMed
13.
Zurück zum Zitat Luhmann J, Kennedy R, Porter F, Miller J, Jaffe D (2001) A randomized clinical trial of continuous flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med 37:20–27CrossRefPubMed Luhmann J, Kennedy R, Porter F, Miller J, Jaffe D (2001) A randomized clinical trial of continuous flow nitrous oxide and midazolam for sedation of young children during laceration repair. Ann Emerg Med 37:20–27CrossRefPubMed
14.
Zurück zum Zitat Maze M, Fuginaga M (2000) Recent advances in understanding the actions and toxicity of nitrous oxide. Anaesthesia 55:311–314CrossRefPubMed Maze M, Fuginaga M (2000) Recent advances in understanding the actions and toxicity of nitrous oxide. Anaesthesia 55:311–314CrossRefPubMed
15.
Zurück zum Zitat Roberts G, Wignall B (1982) Efficacy of the laryngeal reflex during oxygen-nitrous oxide sedation. Br J Anaesth 54:1277–1281PubMed Roberts G, Wignall B (1982) Efficacy of the laryngeal reflex during oxygen-nitrous oxide sedation. Br J Anaesth 54:1277–1281PubMed
16.
Zurück zum Zitat Vetter T (1995) A comparison of EMLA versus nitrous oxide for pediatric venous canulation. J Clin Anesth 7:486–490CrossRefPubMed Vetter T (1995) A comparison of EMLA versus nitrous oxide for pediatric venous canulation. J Clin Anesth 7:486–490CrossRefPubMed
Metadaten
Titel
Prospective, double-blind, randomized trial of equimolar mixture of nitrous oxide/oxygen to prevent pain induced by insertion of venous access ports in cancer patients
verfasst von
Marie Cécile Douard
Mario di Palma
Patricia d’Agostino
Sylvie Chevret
Irène Kriegel
Bruno Falissard
Patrick Thierry
Brigitte George
Laurence Bussières
Jean-Louis Misset
Publikationsdatum
01.02.2006
Erschienen in
Supportive Care in Cancer / Ausgabe 2/2006
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0852-1

Weitere Artikel der Ausgabe 2/2006

Supportive Care in Cancer 2/2006 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.